logo

Clinical Trial Results

Share

ObsEva SA's (OBSV) phase III study of Linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids, dubbed PRIMROSE 2, has yielded positive results.

Portola Pharmaceuticals (PTLA) presented new interim results from the company's ongoing phase IIa study of investigational drug cerdulatinib in heavily pre-treated T-Cell malignancies at the 61st annual meeting of American Society of Hematology (ASH) in Orlando on Sunday.

pharma-032118_08dec19.jpg The following are some of the companies that presented new/updated trial data of their investigational drug candidates at the 61st Annual Meeting of the American Society of Hematology (ASH) on Saturday.

pharma-061217_06dec19.jpg Obseva SA (OBSV), a specialty biopharmaceutical company operating in the field of women's health and reproductive medicine, awaits a key catalyst on Monday.

Novartis (NVS) announced data from the 52-week Phase III PALLADIUM trial which showed that QMF149, a fixed-dose combination of indacaterol acetate and mometasone furoate, was superior to mometasone furoate at medium and high doses in improving lung function, meeting the primary endpoint. Statistically...

pharmaup-dec02.jpg The following are some of today's top gainers in the healthcare sector.

Sirona Biochem Corp. (SBM.V) (SRBCF.OB) announced that its investigative skin lightening compound TFC-1067 has been successfully completed a toxicology test for an increased dose of 0.4%, in preparation for the new clinical study.

Myovant Sciences (MYOV) announced the Phase 3 HERO study of oral relugolix (120 mg) met its primary efficacy endpoint and all six key secondary endpoints in men with advanced prostate cancer. The results support a New Drug Application submission to the FDA in the second quarter of 2020. In the primary...

myovant-nov19.jpg Myovant Sciences Ltd. (MYOV) is slated to present results from its phase III study of once-daily, oral Relugolix in men with advanced prostate cancer on Tuesday, November 19, 2019.

Karuna Therapeutics, Inc. (KRTX) reported results from its Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia. The company said KarXT showed a statistically significant and clinically meaningful 11.6 point mean reduction in total Positive and Negative...

resTORbio, Inc., (TORC) said that data from the PROTECTOR 1 Phase 3 study, which evaluated the safety and efficacy of RTB101 in preventing clinically symptomatic respiratory illness in adults age 65 and older, did not meet its primary endpoint. It has stopped the development of RTB101 in this indication....

VistaGen Therapeutics (VTGN) announced Phase 2 results for AV-101 as an adjunctive treatment of major depressive disorder or MDD, reporting that the AV-101 treatment arm did not differentiate from placebo on the primary endpoint. AV-101 was well tolerated, with no psychotomimetic side effects or serious...

British drug major AstraZeneca (AZN.L, AZN) announced Tuesday positive Phase III TULIP 2 trial for anifrolumab, a potential new medicine for the treatment of moderate to severe systemic lupus erythematosus or SLE. The company noted that Anifrolumab demonstrated superiority across multiple efficacy...

Swiss drug major Novartis AG (NVS) announced detailed results from the Phase III PREVENT trial that evaluates the efficacy and safety of Cosentyx, or secukinumab, in patients with non-radiographic axial spondyloarthritis or nr-axSpA. According to Novartis, the ongoing trial met its primary endpoint...

confetrence-nov11.jpg The announcement of clinical trial results is a major market-moving event for pharma/biotech stocks. Listed below are some of the pharma/biotech stocks to watch out for today and tomorrow.

Follow RTT
>